Company Overview and News

 
Abbott gets reprieve from Supreme Court in FDC ban case

2018-09-10 moneycontrol
Shares of Abbott India rose 2.54 percent on the BSE on September 10, after Supreme Court (SC) directed the government to lift the ban on 15 fixed dose combination (FDC) medications that were approved before 1988.
ABBOTINDIA 500488

 
Check out the top 10 stocks which moved the most last week

2018-09-02 moneycontrol
Equities did not have the best of their starts to a new series, with the Nifty ending the first day of September series below 11,700-mark. However, bulls did manage to battle it out well with the bears as the market was off its low points.
500219 ABBOTINDIA 570004 RELEY RIFS 539254 RELFF 532627 JISLJALEQS TCHQY 532778 532755 TECHM 500390 RELINFRA JISLDVREQS RIFA JPPOWER 500488 LITL ADANITRANS

 
Abbott India lines up 100 product launches over the next 5 years

2018-08-26 moneycontrol
Drug major Abbott India aims to launch around 100 products over the next five years as it looks to strengthen existing therapy areas as well as grow over-the-counter portfolio, a top company official said.
ABBOTINDIA 500488

1
D-Street Buzz: Midcap stocks gain led by CG Power; Dr Reddy#39;s Labs jumps 2%, INOX Leisure zooms 10%

2018-08-03 moneycontrol
The Indian benchmark indices have bounced back this Friday morning with the Sensex trading higher by 288 points at 37,453 while the Nifty has jumped 89 points and is trading at 11,333.
ABBOTINDIA PWQFY 500325 AUROPHARMA RELIANCE 532617 INOXLEISUR JISLJALEQS 533155 514034 532810 JUBLFOOD 535789 500470 532187 JBFIND RIGD JBLWY HDFCBANK GAILF RLNIY 500219 YESBANK 570004 524804 INDUSINDBK 532706 IDKQY JETAIRWAYS 532648 YYBKY IBULHSGFIN PFC TTST TATASTEEL TATLY HDB 500180 JISLDVREQS ARBQY GAILY 500488

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...